Clinical Trials Logo

Papulopustular Rosacea clinical trials

View clinical trials related to Papulopustular Rosacea.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06013371 Recruiting - Clinical trials for Papulopustular Rosacea

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Subjects will be randomized 2:1 to receive study drug or placebo. Enrolled subjects will apply topical PF-07038124 0.02% ointment once daily for 8 weeks. They will return for visits at weeks 4, 8, and 12 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events.

NCT ID: NCT03864978 Recruiting - Clinical trials for Papulopustular Rosacea

Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

Start date: June 22, 2018
Phase: Phase 2
Study type: Interventional

Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.